Akari Therapeutics Files 8-K on Officer/Director Changes
Ticker: AKTX · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1541157
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, financial-statements
Related Tickers: AKTX
TL;DR
Akari Therapeutics 8-K: Board and exec shakeup, financial updates filed.
AI Summary
Akari Therapeutics Plc filed an 8-K on June 5, 2024, reporting events as of May 31, 2024. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership and the filing of financial statements can introduce uncertainty and signal potential strategic shifts or financial performance issues.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
- June 5, 2024 (date) — Date of report
- 22 Boston Wharf Road FL 7 (location) — Business and Mail Address
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided excerpt.
What is the significance of the 'Compensatory Arrangements of Certain Officers' mentioned in the filing?
This item suggests that the company is disclosing information about the compensation packages for its key executives, which can be material to investors.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 31, 2024.
What are the primary business activities of Akari Therapeutics Plc?
Akari Therapeutics Plc is classified under 'PHARMACEUTICAL PREPARATIONS' with SIC code 2834.
What previous names has Akari Therapeutics Plc used?
The company was formerly known as Celsus Therapeutics Plc. (name change effective June 21, 2013) and Morria Biopharmaceuticals PLC (name change effective February 1, 2012).
Filing Stats: 727 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-05 17:00:15
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
- $50,000 — ecutive Officer, Dr. Patel will be paid $50,000 per month, which will be paid in the fo
Filing Documents
- aktx-20240531.htm (8-K) — 49KB
- aktx-ex10_1.htm (EX-10.1) — 47KB
- 0000950170-24-069414.txt ( ) — 324KB
- aktx-20240531.xsd (EX-101.SCH) — 96KB
- aktx-20240531_htm.xml (XML) — 6KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. As previously disclosed, on April 25, 2024, the board of directors (the "Board") of Akari Therapeutics, Plc (the "Company") appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board. In connection with Dr. Patel's appointment as Interim President and Chief Executive Officer, on May 31, 2024, the Company and Dr. Patel entered into an Interim Chief Executive Officer Agreement, effective as of May 1, 2024 (the "Interim CEO Agreement"). The Interim CEO Agreement: Provides for compensation that is entirely equity-based to align with the shareholders of the Company Includes NO annual bonus provision Includes NO eligibility for employee benefits (health care, retirement benefits, supplemental insurances, etc.) Includes NO severance entitlements Pursuant to the Interim CEO Agreement, Dr. Patel will continue to serve as the Company's Interim President and Chief Executive Officer as an independent contractor on an at-will basis. The Interim CEO Agreement can be terminated by the Company immediately for any reason. As the sole compensation for his services as Interim President and Chief Executive Officer, Dr. Patel will be paid $50,000 per month, which will be paid in the form of fully vested ordinary shares of the Company, par value $0.0001 per share (the "Ordinary Shares"), and valued based on the closing price of the Ordinary Shares on the Nasdaq Capital Market on the last day of each month (or partial month) Dr. Patel is serving as Interim President and Chief Executive Officer. The foregoing description of the Interim CEO Agreement is a summary and is qualified in its entirety by reference to the complete terms of the Interim CEO Agreement, which is filed herewith as Exhibit 10.1 and incorporated by referen
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Interim Chief Executive Officer Agreement, dated as of May 31, 2024, by and between the Company and Samir Patel, M.D. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: June 5, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President and Chief Executive Officer